Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). David Zhang appointed Class II director, effective October 7, 2026.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- David Zhang appointed Class II director, effective October 7, 2026
- Biotech development expertise spanning Phase 3 trials, regulatory submissions and commercial-stage drug approvals
- Annual cash retainer $40,000, prorated for service period
- Appointment option valued at $500,000, vesting 1/36 monthly over 36 months
- Full option vesting upon a qualifying change in control
Item 8.01 · Other Events
- Dr. Zhang appointed to Aardvark Therapeutics’ Board effective October 8, 2026
- Board addition may influence governance, strategic oversight, and investor confidence
- Exhibit 99.1 contains the company’s announcement and appointment details
Item EX-99.1 · Exhibit EX-99.1
- David Zhang appointed independent director effective October 7, 2026, strengthening clinical and regulatory expertise
- More than 25 years’ experience across Abivax, Alumis, MyoKardia and Genentech/Roche
- Board addition targets ARD-101 development and regulatory strategy for Prader-Willi Syndrome
- FDA clinical hold on ARD-101 remains a key execution risk for investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.